repagermanium

Repagermanium is a synthetic organogermanium compound (2-carboxyethylgermanium sesquioxide) classified as a small molecule. It acts primarily as a C-C chemokine receptor type 2 (CCR2) antagonist and is being investigated for its potential to reduce inflammation and proteinuria in kidney diseases such as focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease. Repagermanium may also have immunostimulant properties by modulating immune responses, potentially aiding in the recognition and destruction of cancer cells. The drug is under clinical investigation both alone and in combination with angiotensin II receptor blockers (ARBs), such as irbesartan or candesartan, particularly for FSGS, diabetic nephropathies, and COVID-19[1][3][5][6][9].

Brand names

Serocion

Other names

2-carboxyethylgermanium sesquioxide